Zach draws a compelling parallel between GLP-1 drugs and AI, highlighting their potential to reshape the healthcare landscape and societal behaviors around weight loss. As these medications change dietary habits and body composition, they could influence everything from marriage rates to healthcare procedures. The stigma surrounding obesity is not just a challenge; it presents unique opportunities for change and innovation in the industry.
